Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease

Atherosclerosis

Volumn 204, Issue 1, 2009, Pages 267-272

  de Fost, M ^a   Langeveld, M ^a   Franssen, R ^a   Hutten, B A ^a   Groener, J E M ^a   de Groot, E ^a   Mannens, M M ^a   Bikker, H ^a   Aerts, J M F G ^a   Kastelein, J J P ^a   Hollak, C E M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Gaucher disease; HDL cholesterol; Lipoproteins

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMIGLUCERASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIGLUSTAT;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; HUMAN; HYPERTENSION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID ARTERY, COMMON; CAROTID ARTERY, INTERNAL; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; FEMALE; GAUCHER DISEASE; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS;

EID: 67349187413     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.08.027     Document Type: Article

References (28)

1. Morales L.E. Gaucher's disease: a review. Ann Pharmacother 30 4 (1996) 381-388
2. Beutler E., and Grabowski G.A. Gaucher disease. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The metabolic and molecular bases of inherited disease. 7th ed. (1995), McGraw-Hill, New York 2641-2670
3. Lee R.E. The pathology of Gaucher disease. Prog Clin Biol Res 95 (1982) 177-217
4. Pratt P.W., Kochwa S., and Estren S. Immunoglobulin abnormalities in Gaucher's disease, report of 16 cases. Blood 31 5 (1968) 633-640
5. Schneider E.L., Epstein C.J., Kaback M.J., and Brandes D. Severe pulmonary involvement in adult Gaucher's disease, report of three cases and review of the literature. Am J Med 63 3 (1977) 475-480
6. Hollak C., Marodi L., and Biegstraaten M. An observational study of neurological manifestations and other co-morbidities in adult type I Gaucher disease. Abstract presented at the European Working Group on Gaucher Disease. Cambridge (2006)
7. Ginsberg H., Grabowski G.A., Gibson J.C., et al. Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease. Clin Genet 26 2 (1984) 109-116
8. Le N.A., Gibson J.C., Rubinstein A., Grabowski G.A., and Ginsberg H.N. Abnormalities in lipoprotein metabolism in Gaucher type 1 disease. Metabolism 37 3 (1988) 240-245
9. Pocovi M., Cenarro A., Civeira F., et al. Beta-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-alpha-lipoproteinaemia. Lancet 351 9120 (1998) 1919-1923
10. Cenarro A., Pocovi M., Giraldo P., Garcia-Otin A.L., and Ordovas J.M. Plasma lipoprotein responses to enzyme-replacement in Gaucher's disease. Lancet 353 9153 (1999) 642-643
11. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., and Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 62 5 (1977) 707-714
12. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 1 (1989) 8-15
13. Davis P.H., Dawson J.D., Riley W.A., and Lauer R.M. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 104 23 (2001) 2815-2819
14. Jarvisalo M.J., Jartti L., Nanto-Salonen K., et al. Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. Circulation 104 24 (2001) 2943-2947
15. Zimran A., Kay A., Gelbart T., et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 71 6 (1992) 337-353
16. Boot R.G., Hollak C.E., Verhoek M., et al. Glucocerebrosidase genotype of Gaucher patients in The Netherlands: limitations in prognostic value. Hum Mutat 10 5 (1997) 348-358
17. Aerts J.M., and Hollak C.E. Plasma metabolic abnormalities in Gaucher's disease. Baillieres Clin Haematol 10 4 (1997) 691-709
18. Schoonhoven A., Rudensky B., Elstein D., et al. Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta 381 2 (2007) 136-139
19. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 9298 (2001) 2026-2033
20. van der Steeg W.A., Boekholdt S.M., Stein E.A., et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 146 9 (2007) 640-648
21. de Groot E., Hovingh G.K., Wiegman A., et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 109 23 suppl 1 (2004) III33-III38
22. Bots M.L., Hoes A.W., Koudstaal P.J., Hofman A., and Grobbee D.E. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96 5 (1997) 1432-1437
23. von Eckardstein A., and Assmann G. High density lipoproteins and reverse cholesterol transport: lessons from mutations. Atherosclerosis 137 (1998) S7-11
24. Boven L.A., van Meurs M., Boot R.G., et al. Gaucher cells demonstrate a distinct macrophage phenotype, and resemble alternatively activated macrophages. Am J Clin Pathol 122 (2004) 359-369
25. Yan Z.Q., and Hansson G.K. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 219 (2007) 203-287
26. Hovingh G.K., de Groot E., van der Steeg W., et al. Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol 16 2 (2005) 139-145
27. Groener J.E., Poorthuis B.J., Kuiper S., Hollak C.E., and Aerts J.M. Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention. Biochim Biophys Acta 1781 1-2 (2008) 72-78
28. Ghauharali-van der Vlught K., Langeveld M., Poppema A., et al. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta 389 1-2 (2008) 109-113